UNSPSC 51172171: Eperisone hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C17H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U38O8U7P6X, chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-, hydrochloride but more generally known as eperisone hydrochloride, which bears US NIH Compound Identifier 123698. European Medicines Agency schedules Eperisone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01900MIG.

Most nations, for tariff and trade purposes, schedule eperisone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, EPERISONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Eperisone hydrochloride bears US NLM NCI C83693. SMILES: CCC1CCC(CC1)C(=O)C(C)CN2CCCCC2.CL.

UNSPSC 51172171 Eperisone hydrochloride is a Commodity code representing a single muscle relaxant pharmaceutical product, though recent state and local procurement activity under this code designation shows minimal direct purchasing of the drug itself. Instead, state and local governments are procuring drug testing services, pharmaceutical supply chain infrastructure, and pharmacy benefit management capabilities that may encompass eperisone among broader product portfolios. The issuing bodies span county criminal justice departments, state health and human services agencies, and multistate cooperative purchasing alliances; these entities are buying specimen collection and testing services, direct-to-manufacturer prescription fulfillment capacity, and generic pharmaceutical distribution agreements rather than named-drug procurement in isolation.

Recent opportunities illustrate the actual scope of work. Collin County Community Supervision and Corrections Department issued RFP 2026-327, due July 23, 2026, for offender specimen collection and drug testing services across two Texas sites, with an estimated contract value of $600,000 and a two-year base term with three optional one-year renewals; the county seeks lab-certified vendors offering immunoassay screening with confirmatory analysis and alternative testing methodologies. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs that would enable state pharmacy benefit programs to bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers with an effective date of July 1, 2026. Geographic activity centers on Texas and Minnesota; the MMCAP solicitation extends to participating states including Oregon. The code's recent activity reflects state and local procurement of pharmaceutical logistics, testing infrastructure, and supply-chain intermediation rather than direct acquisition of individual drugs by name.